EMA: Faulty device didn’t distort study findings for Bayer’s Xarelto

Carly Helfand

Last December, European regulators said they were no longer sure whether results from a trial of Bayer's new-age clot-buster  were accurate thanks to a defect in a blood-clotting testing used in the . But the German pharma can breathe easy now.


FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS